QED Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.qedtx.com
An Interventional Study of Infigratinib in Children With Hypochondroplasia
- Conditions
- Hypochondroplasia
- Interventions
- Drug: infigratinib 0.128 mg/kg/day
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06873035
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴Paediatric Clinical Research Unit at Osla University Hospital, Oslo, Norway
🇵🇹Hospital Pediátrico de Coimbra, Coimbra, Portugal
Prospective Clinical Assessment Study in Children with Hypochondroplasia
- Conditions
- Hypochondroplasia
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06410976
- Locations
- 🇫🇷
Hôpital Universitaire Necker-Enfants Malades, Paris, France
🇫🇷Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants, Toulouse, France
🇩🇪University Hospital Freiburg - Centre for Paediatric and Adolescent Medicine, Freiburg, Baden-Wurtemberg, Germany
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo Comparator 0.25 mg/kg/day
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06164951
- Locations
- 🇬🇧
QED Investigative Site, Sheffield, United Kingdom
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05145010
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸USCF Benioff Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
Study of Infigratinib in Children with Achondroplasia
- Conditions
- Achondroplasia
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04265651
- Locations
- 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸UCSF Benioff Children's Hospital, Oakland, California, United States
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- Conditions
- Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04197986
- Locations
- 🇺🇸
The Ohio State University College of Medicine, Columbus, Ohio, United States
🇺🇸Associated Medical Professionals - Syracuse, Syracuse, New York, United States
🇺🇸New Jersey Urology - Saddle Brook, Saddle Brook, New Jersey, United States
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
- Conditions
- Achondroplasia
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 271
- Registration Number
- NCT04035811
- Locations
- 🇨🇦
University of Montreal, Montréal, Quebec, Canada
🇫🇷Hopital Femme Mere Enfant, Lyon, France
🇫🇷Hopital Necker-Enfants Malades, Paris, France
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
- Conditions
- Advanced CholangiocarcinomaFGFR2 Gene Mutation
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03773302
- Locations
- 🇺🇸
Parkland Health and Hospital System, Dallas, Texas, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
- Conditions
- Advanced CholangiocarcinomaFGFR2 Gene Mutation
- Interventions
- Drug: BGJ398 (infigratinib)
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT02150967
- Locations
- 🇬🇧
QED Investigative Site, Nottingham, United Kingdom